Date:3/3/2008

cies related to the sale of the worldwide rights to Nipent and Surface Safe to Mayne Pharma, and the ability of MGI to generate global sales of Dacogen. In general, our future success is dependent upon numerous factors, including our ability to generate pre-clinical development candidates for selection into clinical testing, obtaining regulatory approval of product development programs, conducting and completing clinical trials and obtaining regulatory approval of our products and product candidates, and creating opportunities for future commercialization of compounds. Our future revenue and operating and net income or loss could be worse than anticipated if demand for our products is less than expected, or if the introduction of new products is delayed, for any reason, including regulatory delay. References made to the discussion of risk factors are detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Manager, Investor Relations

Communications Tel: (925) 560-2845

& Business Development

Tel: (925) 560-0100 x111

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com

SUPERGEN, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

Three Months Year'/>"/>

SOURCE SuperGen Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter